Psycho-Babble Medication Thread 1106098

Shown: posts 1 to 7 of 7. This is the beginning of the thread.

Cyproheptadine potential movement disorder risk?

Posted by iforgotmypassword on September 11, 2019, at 13:23:59

It was often used to treat akathisia but it looks like it might b a very potent D3 receptor antagonist, and the receptor has been speculated to be even more involved in acquired involuntary movements than D2.

Just thought I would leave a note as I never recalled this coming up--but if it's true, not something to ignore.

Re: Cyproheptadine potential movement disorder risk?

Posted by linkadge on September 11, 2019, at 14:54:26

In reply to Cyproheptadine potential movement disorder risk?, posted by iforgotmypassword on September 11, 2019, at 13:23:59

From my understanding the d3 occupancy was very low (as compared with other receptors). Do you have a reference for a higher value?

Linkadge

Re: Cyproheptadine potential movement disorder risk?

Posted by Christ_empowered on September 12, 2019, at 19:03:33

In reply to Re: Cyproheptadine potential movement disorder risk?, posted by linkadge on September 11, 2019, at 14:54:26

does this mean that vraylar could cause lots of TD?

Re: Cyproheptadine potential movement disorder risk?

Posted by linkadge on September 14, 2019, at 13:41:44

In reply to Re: Cyproheptadine potential movement disorder risk?, posted by Christ_empowered on September 12, 2019, at 19:03:33

I think vrylar is a d3 agonist (or partial agonist) rather than an antagonist.

Linkadge

Re: Cyproheptadine potential movement disorder risk?

Posted by SLS on September 14, 2019, at 22:49:12

In reply to Re: Cyproheptadine potential movement disorder risk?, posted by linkadge on September 14, 2019, at 13:41:44

> I think vrylar is a d3 agonist (or partial agonist) rather than an antagonist.
>
> Linkadge

Vraylar has a higher ratio of D3/D2 partial agonism compared to Abilify.

Rexulti has a lower ratio of D3/D2 partial agonism compared to Abilify.

I found Rexulti to be less helpful for depression than Abilify, but was generally benign. I became much worse immediately upon starting Vraylar. I didn't dare continue taking it beyond 4 days. Its active metabolilte has a half-life of 1-3 weeks.

- Scott

Re: Cyproheptadine potential movement disorder risk? » linkadge

Posted by iforgotmypassword on September 24, 2019, at 2:37:49

In reply to Re: Cyproheptadine potential movement disorder risk?, posted by linkadge on September 11, 2019, at 14:54:26

wikipedia links to this https://pdsp.unc.edu/databases/pdsp.php?receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=cyproheptadine&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query

Re: Cyproheptadine potential movement disorder risk? » iforgotmypassword

Posted by linkadge on September 29, 2019, at 7:20:19

In reply to Re: Cyproheptadine potential movement disorder risk? » linkadge, posted by iforgotmypassword on September 24, 2019, at 2:37:49

Hey,

I saw that. The only thing though is that for the d3 receptor, it's affinity is (apparently) based on only one study. If you go to the PDSP ki database:

https://pdsp.unc.edu/databases/pdsp.php?receptorDD=&receptor=&speciesDD=&species=&sourceDDRadio=sourceDDRadio&sourcesDD=&source=&hotLigandDD=&hotLigand=&testDDRadio=testDDRadio&testLigandDD=1164&testLigand=&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query

you can see there are dozens of entries for 5-ht2a and only one for d3. The results for affinity are highly variable. It's possible that it's accurate, but hard to tell with only one entry.

This is the end of the thread.

Show another thread

Psycho-Babble Medication | Extras | FAQ

Dr. Bob is Robert Hsiung, MD, bob@dr-bob.org

Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.